Success Rate of IUI with PCOS: What the Data Shows

You have done a few cycles of letrozole or clomid with timed intercourse and your RE is now suggesting IUI. Or you have just finished your first medicated IUI and want to know what the published numbers say about your odds versus the women in the IUI-for-unexplained trials. The PCOS-specific data is good, it is more nuanced than most blog posts make it sound, and that nuance is the difference between a well-monitored cycle and one that should have been cancelled.

The headline. The success rate of IUI with PCOS is broadly comparable to unexplained-infertility cohorts once ovulation is reliably induced, with letrozole-IUI outperforming clomid-IUI on live birth (the PALM/PPCOS-II trial in NEJM 2014).¹ The PCOS-specific story is less about the procedure and more about the medication driving the ovulation, the monitoring around follicle count, and the twin risk that comes with more than one mature follicle.

What PCOS actually changes about an IUI cycle

The IUI procedure itself is the same in PCOS as in any other diagnosis. Washed sperm goes into the uterine cavity past the cervix, at the time of ovulation, through a soft catheter. What PCOS changes is everything that happens in the two weeks leading up to that moment.

In a PCOS cycle, the medication is doing the heavy lifting. Letrozole or clomid is being used to drive ovulation, because the underlying issue in PCOS is anovulation or oligo-ovulation, not the sperm-meets-egg part. The IUI is a small probability bump on top of an ovulation that the meds had to create. This matters because the levers your RE has to adjust between cycles are the medication, the dose, and how aggressively they will let the ovaries respond, not the IUI procedure itself.

The biggest PCOS-specific risk is over-response. PCOS ovaries have a high antral follicle count and are unusually sensitive to FSH stimulation. A cycle that produces three or four mature follicles in a person with PCOS is not unusual, and three or four mature follicles is too many for a safe IUI.

This is the reason monitoring is non-negotiable in PCOS-IUI cycles. You cannot fly blind. A transvaginal ultrasound around cycle day 10 to 12, with an estradiol measurement, is the standard. Many clinics will cancel the cycle or convert it to abstinence if three or more follicles look likely to ovulate. The international PCOS guideline and ASRM committee opinion on gonadotropins both support that cancellation threshold for safety reasons.²^,⁴

Success rate of IUI with PCOS: the headline numbers

The IUI success rate with letrozole in PCOS is the number most readers are looking for, so I will put it first.

Per-cycle live birth for letrozole-IUI in PCOS in someone under 35 with a normal partner sample typically runs 10 to 18 percent. Across three to four cycles, cumulative live birth in younger PCOS patients with no other factor approaches 30 to 40 percent. These ranges sit in the same ballpark as IUI for unexplained infertility, which is the important point. PCOS does not make IUI fail. PCOS makes the ovulation step harder, and once the ovulation step is fixed, the IUI part behaves more or less like any other cycle.

The PALM/PPCOS-II trial is the landmark here.¹ It randomised 750 PCOS patients to letrozole or clomid for up to five treatment cycles using a timed-intercourse and IUI-hybrid protocol. The letrozole arm achieved 27.5 percent live birth across five cycles compared with 19.1 percent in the clomid arm. The ovulation rates were also higher with letrozole. This is the data that moved letrozole to first-line for PCOS in ASRM, ESHRE, and the 2023 international PCOS guideline (Teede and colleagues).²

Adding IUI to ovulation induction in PCOS adds a small but real per-cycle bump versus timed intercourse alone, particularly in cycles where the partner sample is borderline or where cervical factor is suspected. The Cochrane review of IUI versus timed intercourse supports the addition in unexplained subfertility cohorts.⁵ For PCOS specifically the data is mixed but the consensus is that IUI is a reasonable next step after a few cycles of ovulatory timed-intercourse cycles that did not produce a pregnancy.

Letrozole versus clomid in PCOS-IUI

The clomid and IUI success rate is a search term, but it is the wrong question for PCOS readers. The PALM data is clear that letrozole outperforms clomid on the outcome that matters, which is live birth.¹ I want to take a paragraph on why.

Letrozole is an aromatase inhibitor. It briefly lowers the body's oestrogen, which removes oestrogen feedback to the pituitary, which raises FSH, which drives follicle growth. The result is a more physiologic-looking cycle, often with a single dominant follicle, and a relatively short pharmacologic footprint (letrozole's half-life is about two days). Clomid is a selective oestrogen receptor modulator. It blocks oestrogen receptors centrally, which produces a similar rise in FSH, but it also produces well-documented antioestrogenic effects on the endometrium and cervical mucus. Thinner linings and reduced fertile-window mucus mean that even when clomid drives an ovulation, the rest of the cycle is sometimes working against itself.

In PCOS specifically, three things favour letrozole. Higher ovulation rates. Higher live birth (the PALM result). A cleaner side-effect profile in most patients, though letrozole produces hot flashes in roughly 30 percent.

If your clinic still starts with clomid for PCOS, ask why. There are legitimate reasons (cost, prior letrozole intolerance, regulatory access in some countries), but the default of clomid because that is how the clinic has always done it is harder to defend in 2026. The deeper comparison is in letrozole-vs-clomid-pcos.

Why over-response is the PCOS-specific risk

The single most important number in a PCOS-IUI cycle is the follicle count at the time of trigger, and the way that number is monitored separates a careful cycle from a careless one.

One mature follicle is the baseline. The per-cycle live birth in someone under 35 with a normal partner sample sits in the 10 to 18 percent range I mentioned earlier. Two mature follicles modestly raises that number into the 15 to 22 percent range. Two follicles is also where twin risk becomes meaningful, in the region of 15 percent compared with the background twin rate of around 1 percent. The 2 follicles IUI success rate searches return a wide range of numbers, but the honest answer is that two follicles is a modest bump in per-cycle pregnancy and a much larger bump in twin risk.

Three or more mature follicles is where most modern clinics will cancel the cycle. The per-cycle pregnancy rate bumps a little further, but the triplet risk becomes non-trivial. Triplet pregnancies have substantially worse maternal and neonatal outcomes. Modern reproductive medicine takes the position that the right strategy is to cancel the cycle, convert to abstinence, or move the patient to IVF, where embryo number is controlled at transfer rather than at ovulation.⁴

Gonadotropin-IUI, where injectable FSH is used to drive follicle growth, is even higher risk in PCOS because PCOS ovaries respond unpredictably to FSH. The ASRM 2020 committee opinion on gonadotropins counsels against gonadotropin-IUI in PCOS specifically.⁴ If your clinic is suggesting injectable stimulation for a PCOS-IUI cycle, ask what is making oral medication insufficient and what the cancellation thresholds will be.

Cancellation rates for PCOS-IUI cycles typically run between 5 and 15 percent depending on protocol and clinic threshold. A cancelled cycle is frustrating, but it is the correct decision when the alternative is a high-order multiple pregnancy.

What the numbers do not show

A few variables that get a lot of forum attention but do not move the per-cycle number as much as people think.

Body mass index has a measurable effect. Every 5 kg/m² above 30 modestly reduces per-cycle live birth in published cohorts, with the largest effect above BMI 35. The effect is dose-dependent, not a cliff, and a 5 to 10 percent reduction in body weight in someone with elevated BMI and PCOS improves both ovulation and reproductive outcomes (the 2023 international PCOS guideline).² This is a sustained-change number, not a crash-diet number.

Insulin sensitisers, mainly metformin, are still in the picture. Metformin improves ovulation rates in PCOS in most studies, but the live-birth signal is smaller than once thought. The Cochrane review of insulin-sensitising drugs concluded that metformin probably improves clinical pregnancy but the live-birth effect is more uncertain.³ If you are not already on metformin and your fasting insulin is elevated, it is a reasonable adjunct for the next cycle. If you are already on it, do not expect it to be the variable that flips a negative cycle.

Hyperandrogenism severity and AMH level do not strongly predict IUI success once ovulation is achieved. A high AMH in PCOS is sometimes treated as a worry signal in the cycle, but for IUI outcomes specifically, what matters is whether the meds produced an ovulation with the right number of follicles, not what the AMH was at baseline.

Older PCOS patients lose the relative advantage that PCOS confers on ovarian reserve. The high antral follicle count and high AMH that come with PCOS can give a 38-year-old PCOS patient a slightly better IVF prognosis than a 38-year-old without PCOS. For IUI specifically, the age-related decline catches up. A PCOS-IUI cycle at 39 looks more like an unexplained-IUI cycle at 39 than a PCOS-IUI cycle at 30.

The honest per-cycle expectation

Putting the pieces together, here is what I tell PCOS patients to expect from a well-monitored letrozole-IUI cycle.

• One mature follicle, normal partner sample, under 35: per-cycle live birth 10 to 18 percent. Twin risk near baseline.
• Two mature follicles, normal partner sample, under 35: per-cycle live birth 15 to 22 percent. Twin risk approximately 15 percent.
• Three or more mature follicles: most clinics will cancel or convert to abstinence; if the cycle proceeds, twin and triplet risk are unacceptable for most modern protocols.
• BMI above 35: subtract a few percentage points from the per-cycle number and have a separate conversation about weight trajectory and stim alternatives before continuing.
• Three consecutive cycles without pregnancy with confirmed ovulation each time: this is the reassessment moment, covered in third-iui-failed-what-now and when-to-skip-iui-go-ivf.

When the math favours moving on

Three to four well-monitored letrozole-IUI cycles is the standard ceiling for PCOS-IUI, supported by NICE NG156 and the consensus of US practice.⁷ If pregnancy has not occurred and ovulation was confirmed each cycle, IUI is unlikely to deliver and IVF becomes the next conversation.

I want to name one thing here, because patients hear it as bad news and it often is not. Younger PCOS patients tend to have one of the better IVF prognoses available in the clinic. High AMH and a high antral follicle count mean retrievals tend to produce more eggs. The challenge in PCOS IVF is calibrating the stimulation carefully enough to avoid ovarian hyperstimulation syndrome (OHSS), and modern antagonist protocols with GnRH-agonist triggers have made that much safer than it was a decade ago. Moving from IUI to IVF in PCOS is not a setback. It is a different tool being applied to a different barrier.

Questions to ask before your next PCOS-IUI cycle

A short list to bring to the consult.

1. Are we on letrozole or clomid, and what is the reasoning given my history?
2. What is the target follicle number and what is the cancellation threshold?
3. Will we add metformin if I am not already on it? What does my fasting insulin look like?
4. What is my partner's most recent post-wash total motile sperm count?
5. How many cycles before we reassess, and what would trigger an earlier reassessment?

A clinic that can answer these clearly is a clinic that is thinking about your cycle individually. A clinic that defaults to a protocol without these answers is one to push.

What you can do this cycle

Two practical pieces.

Track the variables that matter between cycle 1 and cycle 2. Trigger date. Follicle count and the largest follicle's diameter at trigger. Endometrial thickness. Post-wash total motile count if your clinic shares it. The medication you took and on which days. If cycle 1 was negative, those data points are the basis of the cycle 2 conversation with your RE.

Be honest about side effects. Letrozole hot flashes, mood changes on clomid, and bloating are worth naming. They are not a sign that the medication is failing; they are usually a sign that the medication is doing what it is designed to do. If side effects are intolerable, the right move is a medication change, not stopping treatment. The success rate of IUI with PCOS tracks the cycles that get monitored and adjusted, not the ones that run on autopilot.

What's next

• If you are in cycle 1 and waiting on the beta: luteal phase explained
• If your partner's semen analysis is the next variable: iui-sperm-count-requirements
• If you are weighing medicated vs natural cycle: medicated-vs-unmedicated-iui
• If you are choosing between letrozole and clomid: letrozole-vs-clomid-pcos
• If three IUIs have not worked: when-to-skip-iui-go-ivf
• For the broader age-and-diagnosis view: iui-success-rates-by-age

Sources

1. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (PPCOS-II/PALM). New England Journal of Medicine 2014;371(2):119-129. Link
2. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility 2023;120(4):767-793. Link
3. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2017;(11):CD003053. Link
4. Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion. Fertility and Sterility 2020;113(1):66-70. Link
5. Veltman-Verhulst SM, Hughes E, Ayeleke RO, Cohlen BJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database of Systematic Reviews 2016;(2):CD001838. Link
6. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility 2013;100(2):341-348. Link
7. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment. NICE guideline NG156. 2013, updated 2017. Link